692059-53-3

Upstream product

• 557771-28-5 7-fluoro-5-isopropoxyquinazolin-4(3H)-one 
• 7314-44-5 2,4-dimethoxylbenzyl alcohol 
• 692059-64-6 7-(2, 4-dimethoxybenzyloxy)-5-isopropoxy-3,4-dihydroquinazolin-4-one 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 379228-58-7 5,7-difluoroquinazolin-4(3H)-one 

Downstream Products

• 719304-92-4 4-(5-chloro-2-methoxypyridin-4-ylamino)-7-(2, 4-dimethoxybenzyloxy) - 5-isopropoxyquinazoline 
• 768360-27-6 (2-chloro-5-methoxy-pyridin-3-yl)-[7-(2,4-dimethoxy-benzyloxy)-5-isopropoxy-quinazolin-4-yl]-amine 

Relevant academic research and scientific papers

New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors

A series of 5,7-disubstituted quinazolines, bearing 4-heteroaryl substituents such as 2-pyridinylamine or 2-pyrazinylamine, has been synthetised and evaluated as c-Src kinase inhibitors. Highly potent inhibition, high selectivity and physical properties suitable for oral dosing were achieved within this series: 23d and 42 were identified as sub-0.1 μM inhibitors in a c-Src-driven cell proliferation assay and displayed adequate rat pharmacokinetics after oral administration.

QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I ) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-6C)alkyl, m is 1, 2 or 3

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group is selected from halogeno, (1-8C)alkyl, (1-6C)alkoxy and any of the other meanings defined in the description, Ra is hydrogen or halogeno, Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy, Rc is hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, and Rd is (1-6C)alkoxy, or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

PYRAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3,

4-PYRIMIDINYL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS

The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N (R2) or C (R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C) alkyl, m is 1, 2 or

4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS

The invention concerns quinazoline derivatives of Formula (I): wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-6C)alkyl, m is 1, 2 or 3